keyword
MENU ▼
Read by QxMD icon Read
search

third-line

keyword
https://www.readbyqxmd.com/read/29142753/long-term-survival-in-a-patient-with-metastatic-squamous-cell-lung-carcinoma-a-case-report
#1
Emiddio Barletta, Piera Federico, Vincenza Tinessa, Domenico Germano, Lucia Cannella, Teresa Pironti, Bruno Daniele
Non-small-cell lung cancer (NSCLC) is the most common malignancy in industrialized countries, with a 5-year survival rate of only ~15%, as the majority of the patients have advanced-stage disease at diagnosis and the treatment options are limited. Squamous cell carcinoma the second most frequent type of NSCLC and is closely associated with cigarette smoking. We herein present the case of a 72-year-old male smoker, diagnosed with stage IV squamous cell lung carcinoma, with a solitary brain metastasis. After the diagnosis, stereotactic radiotherapy was performed on the brain metastasis...
November 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29140932/characteristics-of-treatment-experienced-hiv-infected-african-children-and-adolescents-initiating-darunavir-and-or-etravirine-based-antiretroviral-treatment
#2
Bethany Corrigan, Irene Mukui, Lloyd Mulenga, Nobuhle Mthethwa, Mosilinyane Letsie, Stephanie Bruno, Natella Rakhmanina
BACKGROUND: Data are limited on the selection and sequencing of second and third-line pediatric antiretroviral treatment (ART) in resource-limited settings. This study aimed to evaluate characteristics of African pediatric patients initiated on darunavir (DRV) and/or etravirine (ETR) through a specific drug donation program. METHODS: This was a cross-sectional study of baseline immunologic, virologic and demographic characteristics of children and adolescents initiating DRV- and/or ETR-based ART...
November 14, 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/29139090/tofacitinib-a-review-in-rheumatoid-arthritis
#3
Sohita Dhillon
Tofacitinib (Xeljanz(®)) is a potent, selective JAK inhibitor that preferentially inhibits Janus kinase (JAK) 1 and JAK3. In the EU, oral tofacitinib 5 mg twice daily is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant of, one or more DMARDs. Several clinical studies of ≤ 24 months' duration showed that tofacitinib monotherapy (as first- or second-line treatment) and combination therapy with a conventional synthetic DMARD (csDMARD; as second- or third-line treatment) was effective in reducing signs and symptoms of disease and improving health-related quality of life (HR-QOL), with benefits sustained during long-term therapy (≤ 96 months)...
November 14, 2017: Drugs
https://www.readbyqxmd.com/read/29138154/pharmacologic-management-of-chronic-neuropathic-pain-review-of-the-canadian-pain-society-consensus-statement
#4
REVIEW
Alex Mu, Erica Weinberg, Dwight E Moulin, Hance Clarke
OBJECTIVE: To provide family physicians with a practical clinical summary of the Canadian Pain Society (CPS) revised consensus statement on the pharmacologic management of neuropathic pain. QUALITY OF EVIDENCE: A multidisciplinary interest group within the CPS conducted a systematic review of the literature on the current treatments of neuropathic pain in drafting the revised consensus statement. MAIN MESSAGE: Gabapentinoids, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors are the first-line agents for treating neuropathic pain...
November 2017: Canadian Family Physician Médecin de Famille Canadien
https://www.readbyqxmd.com/read/29137908/no-evidence-found-for-an-association-between-prednisone-dose-and-fvc-change-in-newly-treated-pulmonary-sarcoidosis
#5
Caroline E Broos, Linda H C Poell, Caspar W N Looman, Johannes C C M In 't Veen, Marco J J H Grootenboers, Roxane Heller, Leon M van den Toorn, Monique Wapenaar, Henk C Hoogsteden, Mirjam Kool, Marlies S Wijsenbeek, Bernt van den Blink
BACKGROUND: Prednisone is used as first-line therapy for pulmonary sarcoidosis. What dosing strategy has the best balance between effect and side-effects is largely unknown. We analyzed change in forced vital capacity (FVC) and weight during different prednisone doses used in daily practice for treatment naïve pulmonary sarcoidosis patients. METHODS: Multilevel models were used to describe FVC and weight change over time. Correlations were calculated using linear regression models...
October 31, 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/29134767/availability-and-approval-of-cannabis-based-medicines-for-chronic-pain-management-and-palliative-supportive-care-in-europe-a-survey-of-the-status-in-the-chapters-of-the-european-pain-federation
#6
N Krcevski-Skvarc, C Wells, W Häuser
BACKGROUND: There is considerable public and political interest in the use of cannabis products for medical purposes. METHODS: The task force of the European Pain Federation (EFIC) conducted a survey with its national chapters representatives on the status of approval of all types of cannabis-based medicines, the covering of costs and the availability of a position paper of a national medical association on the use of medical cannabis for chronic pain and for symptom control in palliative/supportive care...
November 13, 2017: European Journal of Pain: EJP
https://www.readbyqxmd.com/read/29129559/treatment-and-survival-outcome-of-braf-mutated-metastatic-colorectal-cancer-a-retrospective-matched-case-control-study
#7
Hamzeh Kayhanian, Emily Goode, Francesco Sclafani, Joo Ern Ang, Marco Gerlinger, David Gonzalez de Castro, Scott Shepherd, Clare Peckitt, Sheela Rao, David Watkins, Ian Chau, David Cunningham, Naureen Starling
BACKGROUND: Somatic v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation, present in approximately 10% of metastatic colorectal cancer (mCRC) cases, is associated with poor prognosis. Patient outcome outside of clinical trials has only been reported in small series. We report real-world data on treatment and survival for BRAF-mutated (MT) patients at a single tertiary center, compared with a matched BRAF wild type (WT) control group. PATIENTS AND METHODS: All colorectal cancer patients tested for BRAF mutation, from October 2010 to November 2014 were identified...
October 16, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29129435/etirinotecan-pegol-nktr-102-in-third-line-treatment-of-patients-with-metastatic-or-recurrent-non-small-cell-lung-cancer-results-of-a-phase-ii-study
#8
Charu Aggarwal, Roger B Cohen, Eddy Yu, Wei-Ting Hwang, Joshua M Bauml, Evan Alley, Tracey L Evans, Corey J Langer
BACKGROUND: Third-line treatment options are limited for patients with metastatic non-small-cell lung cancer (NSCLC). Etirinotecan pegol (NKTR-102) is a long-acting topoisomerase-I inhibitor. We conducted a single-arm phase II trial to evaluate its efficacy in third-line treatment. PATIENTS AND METHODS: Patients aged ≥ 18 years with histologically proven NSCLC who had received 2 previous systemic therapy regimens, measurable disease, Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1, and adequate end-organ function were eligible...
October 19, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29129089/systemic-therapy-for-esophageal-cancer-chemotherapy
#9
Geoffrey Y Ku
As one-half of patients with esophagogastric cancer (EGC) present with metastatic disease and the majority of patients with locally advanced disease will eventually develop metastatic disease despite multimodality therapy, most patients will receive palliative chemotherapy at some point. The reference first-line regimen consists of a fluoropyrimidine/platinum combination, which is the standard in East Asia, where this disease is endemic. Options include infusional 5-fluorouracil (5-FU), capecitabine, S-1 and other oral 5-FU pro-drugs and cisplatin or oxaliplatin...
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29124328/efficacy-of-combination-chemotherapy-using-irinotecan-and-nedaplatin-for-patients-with-recurrent-and-refractory-endometrial-carcinomas-preliminary-analysis-and-literature-review
#10
Morikazu Miyamoto, Masashi Takano, Mika Kuwahara, Hiroaki Soyama, Kento Kato, Hiroko Matuura, Takahiro Sakamoto, Kazuki Takasaki, Tadashi Aoyama, Tomoyuki Yoshikawa, Kenichi Furuya
PURPOSE: We aimed to retrospectively evaluate the efficacy and toxicity of an irinotecan hydrochloride (CPT) and nedaplatin (N) combination therapy for recurrent and refractory endometrial carcinoma, administered based on UGT1A1 genotype. METHODS: Between 2009 and 2017, 21 patients who received CPT-N therapy for recurrent endometrial carcinoma as second- or third-line chemotherapy at our hospital were identified. The CPT-N regimen included 40-70 mg/m(2) of CPT-11 on days 1, 8, and 15, and 50 mg/m(2) of nedaplatin on day 1, q4 weeks...
November 9, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29124007/immunotherapy-shock-with-vitiligo-due-to-nivolumab-administration-as-third-line-therapy-in-lung-adenocarcinoma
#11
Paul Zarogoulidis, Haidong Huang, Theodora Tsiouda, Chrysa Sardeli, Georgia Trakada, Lemonia Veletza, Anastasios Kallianos, Christoforos Kosmidis, Aggeliki Rapti, Liana Papaemmanouil, Dimitrios Hatzibougias, Dimitrios Drougas, Chong Bai, Wolfgang Hohenforst-Schmidt
Non-small cell lung cancer is still diagnosed at late stage due to the lack of early symptoms and methods of diagnostic prevention. In the past ten years several targeted therapies have been introduced or explored. Tyrosine kinase inhibitors and immunotherapy are currently considered the most effective and safe therapies in comparison to the non-specific cytotoxic agents. Regarding tyrosine kinase inhibitors the adverse effects have been fully explored, however; on the other hand for immunotherapy there are still several issues to be clarified...
2017: Respiratory Medicine Case Reports
https://www.readbyqxmd.com/read/29123433/real-world-practice-patterns-for-patients-with-advanced-non-small-cell-lung-cancer-multicenter-retrospective-cohort-study-in-japan
#12
Hiroshi Isobe, Kiyoshi Mori, Koichi Minato, Hideki Katsura, Kazuko Taniguchi, Ashwini Arunachalam, Smita Kothari, Xiting Cao, Terufumi Kato
Background: Recommended therapies for advanced/metastatic non-small cell lung cancer (NSCLC) have changed with the advent of targeted therapies. The objectives of this retrospective chart review study were to describe treatment patterns, biomarker testing practices, and health care resource use for advanced NSCLC at 5 sites in Japan. Patients and methods: We studied anonymized medical record data of patients aged ≥18 years who initiated systemic therapy for newly diagnosed stage IIIB or IV NSCLC from January 2011 through June 2013...
2017: Lung Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/29110922/cost-effectiveness-of-trifluridine-tipiracil-for-previously-treated-metastatic-colorectal-cancer-in-england-and-wales
#13
Ash Bullement, Stuart Underhill, Ronan Fougeray, Anthony James Hatswell
BACKGROUND: Treatment options at third-line and beyond for patients with late-line metastatic colorectal cancer (mCRC) are limited, and outcomes are poor with best supportive care (BSC). This study investigated the cost-effectiveness of trifluridine/tipiracil and regorafenib relative to BSC alone in patients with mCRC who have been previously treated with, or are not considered candidates for, standard chemotherapies. MATERIALS AND METHODS: A partitioned survival model was constructed to assess the lifetime costs and benefits accrued by patients...
September 28, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29110735/development-of-interstitial-pneumonia-during-treatment-with-eribulin-a-case-report
#14
Kota Nakamura, Motoyasu Kato, Yosuke Miyashita, Osamu Nagashima, Shinichi Sasaki, Shigeru Tominaga, Kazuhisa Takahashi
BACKGROUND: Eribulin is typically used to treat patients with advanced breast cancer, and anti-cancer agents often cause the development of interstitial pneumonia in Japanese patients with advanced cancer. However, few case reports have addressed eribulin-induced interstitial pneumonia. Herein, we report a rare case of interstitial pneumonia-specifically, organized pneumonia-during treatment with eribulin in a patient with advanced breast cancer. CASE PRESENTATION: A 52-year-old Japanese woman was diagnosed as having advanced breast cancer 3 years before the admission described in the present report...
November 6, 2017: BMC Research Notes
https://www.readbyqxmd.com/read/29109299/long-term-trends-in-antidiabetes-drug-usage-in-the-u-s-real-world-evidence-in-patients-newly-diagnosed-with-type-2-diabetes
#15
Olga Montvida, Jonathan Shaw, John J Atherton, Frances Stringer, Sanjoy K Paul
OJBECTIVE: To explore temporal trends in antidiabetes drug (ADD) prescribing and intensification patterns, along with glycemic levels and comorbidities, and possible benefits of novel ADDs in delaying the need for insulin initiation in patients diagnosed with type 2 diabetes. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes aged 18-80 years, who initiated any ADD, were selected (n = 1,023,340) from the U.S. Centricity Electronic Medical Records. Those who initiated second-line ADD after first-line metformin were identified (subcohort 1, n = 357,482); the third-line therapy choices were further explored...
November 6, 2017: Diabetes Care
https://www.readbyqxmd.com/read/29108837/factors-associated-with-type-2-diabetes-mellitus-treatment-choice-across-four-european-countries
#16
Edith M Heintjes, Jetty A Overbeek, Gillian C Hall, Daniel Prieto-Alhambra, Francesco Lapi, Niklas Hammar, Irene D Bezemer
PURPOSE: The aim of this analysis was to identify factors associated with the choice of type 2 diabetes mellitus (T2DM) therapy at the time of intensification of antidiabetic treatment across 4 European countries. METHODS: Antidiabetic drug prescription/dispensing records and patients' characteristics were obtained from the electronic health care records of patients with T2DM from the Netherlands (NL), Italy, and Spain (ES) (all, 2007-2011); and the United Kingdom (UK; 2008-2012)...
November 3, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/29103187/real-world-treatment-patterns-and-effectiveness-among-patients-with-metastatic-colorectal-cancer-treated-with-ziv-aflibercept-in-community-oncology-practices-in-the-usa
#17
Jasmina I Ivanova, Kimberly R Saverno, Jennifer Sung, Mei Sheng Duh, Chen Zhao, Sean Cai, Francis Vekeman, Aaron Peevyhouse, Ravinder Dhawan, Charles S Fuchs
Routine clinical practice data often differ from clinical trials. This study describes real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer (mCRC) receiving ziv-aflibercept in non-academic, community oncology practices in the USA. De-identified electronic medical records from Vector Oncology and Altos Solutions databases were analysed. We identified 218 patients diagnosed with mCRC who had received prior oxaliplatin therapy and initiated ziv-aflibercept as part of second-line or later-line therapy...
November 4, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29100043/treatment-landscape-of-advanced-breast-cancer-patients-with-hormone-receptor-positive-her2-negative-tumors-data-from-the-german-praegnant-breast-cancer-registry
#18
Andreas D Hartkopf, Jens Huober, Bernhard Volz, Naiba Nabieva, Florin-Andrei Taran, Judith Schwitulla, Friedrich Overkamp, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Michael P Lux, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W Beckmann, Erik Belleville, Pauline Wimberger, Carsten Hielscher, Matthias Geberth, Nikos Fersis, Wolfgang Abenhardt, Christian Kurbacher, Rachel Wuerstlein, Christoph Thomssen, Michael Untch, Peter A Fasching, Wolfgang Janni, Tanja N Fehm, Diethelm Wallwiener, Sara Y Brucker, Andreas Schneeweiss
PURPOSE: This study describes comprehensive data from a breast cancer registry concerning the use of endocrine treatment (ET) and chemotherapy in the first, second and higher therapy lines in hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC). METHODS: The PRAEGNANT study is a real-time registry for patients with MBC. Therapies were categorized into the following categories: chemotherapy, aromatase inhibitor (AI), tamoxifen, fulvestrant, or everolimus plus ET and reported for first, second and third line or higher therapy use...
October 26, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29098809/gp41-and-gag-amino-acids-linked-to-hiv-1-protease-inhibitor-based-second-line-failure-in-hiv-1-subtype-a-from-western-kenya
#19
Mia Coetzer, Lauren Ledingham, Lameck Diero, Emmanuel Kemboi, Millicent Orido, Rami Kantor
INTRODUCTION: Failure of protease-inhibitor (PI)-based second-line antiretroviral therapy (ART) with medication adherence but no protease drug resistance mutations (DRMs) is not well understood. This study investigated the involvement of gp41 and gag as alternative mechanisms, not captured by conventional resistance testing and particularly relevant in resource-limited settings where third-line ART is limited. METHODS: We evaluated gp41 and gag for unique amino acids in seven subtype A infected Kenyans failing second-line therapy with no PI resistance yet detectable lopinavir (query dataset), compared to seven similar-setting patients with PI resistance or undetectable lopinavir and 69 publically available subtype A Kenyan whole-genomes sequences...
November 2017: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/29092062/gemcitabine-based-chemotherapy-in-adrenocortical-carcinoma-a-multicenter-study-of-efficacy-and-predictive-factors
#20
Judith E K Henning, Timo Deutschbein, Barbara Altieri, Sonja Steinhauer, Stefan Kircher, Silviu Sbiera, Vanessa Wild, Wiebke Schlötelburg, Matthias Kroiss, Paola Perotti, Andreas Rosenwald, Alfredo Berruti, Martin Fassnacht, Cristina L Ronchi
Context: Adrenocortical carcinoma (ACC) is rare and confers an unfavorable prognosis in advanced stages. Other than combination chemotherapy with cisplatin, etoposide, doxorubicin, and mitotane, the second- and third-line regimens are not well-established. Gemcitabine (GEM)-based chemotherapy was suggested in a phase 2 clinical trial with 28 patients. In other solid tumors, human equilibrative nucleoside transporter type 1 (hENT1) and/or ribonucleotide reductase catalytic subunit M1 (RRM1) expression have been associated with resistance to GEM...
November 1, 2017: Journal of Clinical Endocrinology and Metabolism
keyword
keyword
114246
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"